| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activation of lung metastasis after lymph node dissection
|
Sukhbaatar, A.
|
|
|
29 |
S3 |
p. iii33-iii34
|
article
|
| 2 |
Active immunotherapy with a VEGF targeted vaccine HeberSaVax: The road so far and the future ahead
|
Bequet-Romero, M.
|
|
|
29 |
S3 |
p. iii10
|
article
|
| 3 |
Adjuvant radiation therapy effects systemic immune response cells in female breast cancer patients
|
Lewin, N.
|
|
|
29 |
S3 |
p. iii26
|
article
|
| 4 |
Afatinib is active in osteosarcoma in vitro models
|
Cruz Ramos, M.
|
|
|
29 |
S3 |
p. iii22-iii23
|
article
|
| 5 |
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours
|
Plummer, R.
|
|
|
29 |
S3 |
p. iii9
|
article
|
| 6 |
AKT inhibitors and other new kids on the block
|
Siu, L.
|
|
|
29 |
S3 |
p. iii5
|
article
|
| 7 |
A novel drug conjugate platform: Redefining the therapeutic window for ADCs
|
Babcook, J.
|
|
|
29 |
S3 |
p. iii6
|
article
|
| 8 |
A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors
|
Medina, J.
|
|
|
29 |
S3 |
p. iii10
|
article
|
| 9 |
Antiproliferative effect of trastuzumab and nimotuzumab with EGF on breast cancer cells MCF-7
|
Nikulina, V.
|
|
|
29 |
S3 |
p. iii23-iii24
|
article
|
| 10 |
Antitumor effect of dendritic cells loaded with Fe2O3 magnetic nanocomplex in mice with sarcoma 37
|
Inomistova, M.
|
|
|
29 |
S3 |
p. iii22
|
article
|
| 11 |
A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate
|
Tolcher, A.
|
|
|
29 |
S3 |
p. iii8
|
article
|
| 12 |
A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
|
Blum, K.A.
|
|
|
29 |
S3 |
p. iii7
|
article
|
| 13 |
A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
|
Harb, W.
|
|
|
29 |
S3 |
p. iii7
|
article
|
| 14 |
A polyphenol-rich extract from olive-mill waste waters targets the IL-6/STAT3 pathway in prostate cancer cell lines
|
Albini, A.
|
|
|
29 |
S3 |
p. iii19
|
article
|
| 15 |
Artemisia absinthium extract loaded polymeric nanoparticles as the therapeutic remedy for breast cancer
|
Mughees, M.
|
|
|
29 |
S3 |
p. iii18
|
article
|
| 16 |
Assessment of genetic polymorphisms of CXCR5 on response to therapy of non-Hodgkin lymphoma (NHL)
|
Hashem, T.
|
|
|
29 |
S3 |
p. iii28
|
article
|
| 17 |
A targeted genomic analysis uncovered a large spectrum of acquired resistance mechanisms to BRAF inhibitor therapy in metastatic melanoma patients
|
Louveau, B.
|
|
|
29 |
S3 |
p. iii25-iii26
|
article
|
| 18 |
Augmentation of NAD+ levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates adriamycin-induced cardiomyopathy
|
Khadka, D.
|
|
|
29 |
S3 |
p. iii23
|
article
|
| 19 |
Aurora Kinase A (AURKA) is an independent predictor of recurrence in breast ductal carcinoma in situ (DCIS)
|
Miligy, I.M.
|
|
|
29 |
S3 |
p. iii33
|
article
|
| 20 |
Axitinib: An audit of dose adjustments, tolerability and efficacy in advanced renal cell carcinoma
|
Parkar, R.
|
|
|
29 |
S3 |
p. iii30-iii31
|
article
|
| 21 |
Can adding PI3K inhibitors to the treatment cocktail alter outcome?
|
Lorusso, P.
|
|
|
29 |
S3 |
p. iii5
|
article
|
| 22 |
CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)
|
Michot, J.-M.
|
|
|
29 |
S3 |
p. iii9
|
article
|
| 23 |
CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors
|
Hilton, J.
|
|
|
29 |
S3 |
p. iii8
|
article
|
| 24 |
CellMiner and CellMiner cross-database (CDB): Resources for the exploration of pharmacogenomics using cancerous cell-lines
|
Reinhold, W.
|
|
|
29 |
S3 |
p. iii24
|
article
|
| 25 |
Clinicopathological, predictive and prognostic significance of XRCC1-Ligase III heterodimer expression in ovarian cancer
|
Alabdullah, M.L.
|
|
|
29 |
S3 |
p. iii11
|
article
|
| 26 |
Clinicopathological significance of HER2 and EGFR expression in urothelial carcinoma: A single center study
|
Botiralieva, G.K.
|
|
|
29 |
S3 |
p. iii34
|
article
|
| 27 |
Combination effects of MEK inhibitors with statins on cancer cells
|
Iizuka-Ohashi, M.
|
|
|
29 |
S3 |
p. iii25
|
article
|
| 28 |
Combining PARP inhibitors with CPI
|
Lynce, F.
|
|
|
29 |
S3 |
p. iii2
|
article
|
| 29 |
Comparison of different testing methods for detection of BRAF V600 mutation in metastatic melanoma
|
Hernandez-Losa, J.
|
|
|
29 |
S3 |
p. iii28
|
article
|
| 30 |
Comparison of model-based dose escalation design with rule-based design of phase I oncology trials
|
Shimomura, A.
|
|
|
29 |
S3 |
p. iii26-iii27
|
article
|
| 31 |
Cytotoxicity of methanol extracts of 10 Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines
|
Flora, M.T.
|
|
|
29 |
S3 |
p. iii19-iii20
|
article
|
| 32 |
Delivery of E-cadherin (CDH1) gene and epidermal growth factor receptor (EGFR) siRNA, using carbonate apatite as a promising vehicle in treatment of breast cancer
|
Ashaie, M.A.
|
|
|
29 |
S3 |
p. iii22
|
article
|
| 33 |
Delivery of paclitaxel and everolimus in dual-targeted polymeric nanoparticles to breast cancer cells
|
Houdaihed, L.
|
|
|
29 |
S3 |
p. iii21
|
article
|
| 34 |
Detection of KRAS mutation, MSI and TP53 status in Indonesian CRC patients with its association to PD-L1 expression
|
Kusumo, G.D.
|
|
|
29 |
S3 |
p. iii28
|
article
|
| 35 |
Development of novel modified aptamers to target Axl receptor in ovarian cancer
|
Amero, P.
|
|
|
29 |
S3 |
p. iii17
|
article
|
| 36 |
DNA promoter methylation status and protein expression of SHh and IHh in serous ovarian carcinomas
|
Karin, V.
|
|
|
29 |
S3 |
p. iii14
|
article
|
| 37 |
Downregulation of USP28 confers poorer overall survival to melanoma patients and causes resistance to RAF inhibitors
|
Saei, A.
|
|
|
29 |
S3 |
p. iii9
|
article
|
| 38 |
Drug transporter pharmacogenetics as a predictor of chemotherapy-induced toxicity in lung cancer patients
|
Zair, Z.
|
|
|
29 |
S3 |
p. iii31
|
article
|
| 39 |
Dual inhibition of AXL and FN14 sensitizes cisplatin in resistant non-small cell lung carcinoma by inducing higher caspase 3 cleavage through FHIT upregulation, both in vivo and in vitro
|
Mukherjee, S.
|
|
|
29 |
S3 |
p. iii18
|
article
|
| 40 |
Editorial Board
|
|
|
|
29 |
S3 |
p. ii-iii
|
article
|
| 41 |
Effective model for antitumor drugs screening based on 3D growth system of MCF-7
|
Nikolaienko, T.V.
|
|
|
29 |
S3 |
p. iii21-iii22
|
article
|
| 42 |
Effect of IFNα-2b on migrational ability of tumor cells on early stages of breast cancer development
|
Herheliuk, T.
|
|
|
29 |
S3 |
p. iii24
|
article
|
| 43 |
Effect of prolactin receptor antagonist in different cancer models
|
Al Kharusi, A.
|
|
|
29 |
S3 |
p. iii21
|
article
|
| 44 |
Energy restriction as a novel approach targeting breast cancer stem cells multi-drug resistance
|
Zaher, D.M.
|
|
|
29 |
S3 |
p. iii20-iii21
|
article
|
| 45 |
Epigenetic regulation of tumor metabolism
|
Shivanna, S.
|
|
|
29 |
S3 |
p. iii13-iii14
|
article
|
| 46 |
Erythromycin readthrough of APC nonsense stop codon mutation in Familial adenomatous polyposis
|
Kariv, R.
|
|
|
29 |
S3 |
p. iii29
|
article
|
| 47 |
EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
|
Le Saux, O.
|
|
|
29 |
S3 |
p. iii13
|
article
|
| 48 |
External validation of the Gustave Roussy immune score (GRIm score) in an unselected cohort of patients treated at the Clinica Universidad de Navarra
|
Ceniceros, L.
|
|
|
29 |
S3 |
p. iii26
|
article
|
| 49 |
Functional characterization of mammagliobin-1 isoform in breast cancer
|
Guerrette, R.
|
|
|
29 |
S3 |
p. iii22
|
article
|
| 50 |
Genomic-guided drug discovery: IDH inhibitors - From bench to bedside
|
Schenkein, D.
|
|
|
29 |
S3 |
p. iii2
|
article
|
| 51 |
Hepatocellular carcinoma (HCC) treated with sorafenib (SFB) and hepatitis C virus (HCV) infection
|
Rocha, M.
|
|
|
29 |
S3 |
p. iii32
|
article
|
| 52 |
Identification of chromosomal aberrations using fluorescence in situ hybridization (fish) in bladder cancer patients of south Indian region
|
Kovendan, K.
|
|
|
29 |
S3 |
p. iii29
|
article
|
| 53 |
Identifying the oncogenic role of USP10 as the regulator of PTEN function in breast cancer
|
Kumari, N.
|
|
|
29 |
S3 |
p. iii10-iii11
|
article
|
| 54 |
Impact by age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular targeted agents
|
Ebata, T.
|
|
|
29 |
S3 |
p. iii25
|
article
|
| 55 |
Impact of chronic hepatitis virus infection on the feasibility and efficacy for Asian patients with hepatocellular carcinoma in phase I clinical trials
|
Koyama, T.
|
|
|
29 |
S3 |
p. iii10
|
article
|
| 56 |
Impact of sorafenib on quality of life in hepatocellular carcinoma
|
Abraham, A.M.
|
|
|
29 |
S3 |
p. iii30
|
article
|
| 57 |
Innovative drugs targeting IDO1 functions in neoplasia
|
Grohmann, U.
|
|
|
29 |
S3 |
p. iii1
|
article
|
| 58 |
Insights into the biology of class I PI3K isoforms and translation to the clinic
|
Vanhaesebroeck, B.
|
|
|
29 |
S3 |
p. iii5
|
article
|
| 59 |
In silico identification and in vitro assessment of a potential anticancer peptide sequence retrieved from the Red sea metagenomics library
|
Imam, M.E.
|
|
|
29 |
S3 |
p. iii20
|
article
|
| 60 |
Introduction of a novel cancer cell targeted fusion protein: DT386-BR2
|
Jahanian-Najafabadi, A.
|
|
|
29 |
S3 |
p. iii17-iii18
|
article
|
| 61 |
Investigating the role of nuclear sphingosine kinase 1 (SphK1) in lung cancer
|
Napolitano, F.
|
|
|
29 |
S3 |
p. iii12
|
article
|
| 62 |
Is HER2 positive disease a more aggressive breast cancer sub-type in young women?
|
Anghel, R.
|
|
|
29 |
S3 |
p. iii29-iii30
|
article
|
| 63 |
Is “hyper-progression” a relevant clinical item for patient with solid tumours candidate to check-point inhibitor treatment?
|
de Braud, F.
|
|
|
29 |
S3 |
p. iii5
|
article
|
| 64 |
Kinesin spindle protein inhibitors as novel payload class for ADCs
|
Sommer, A.
|
|
|
29 |
S3 |
p. iii5-iii6
|
article
|
| 65 |
Leptin receptor gene (A/G) polymorphism (rs1137101) and renal cell carcinoma
|
Alhanafy, A.
|
|
|
29 |
S3 |
p. iii16-iii17
|
article
|
| 66 |
M3814: A novel investigational DNA-PK inhibitor to target DNA double strand break repair
|
Zenke, F.T.
|
|
|
29 |
S3 |
p. iii3
|
article
|
| 67 |
MDICT consensus report: Recommendations regarding response criteria, endpoints and study designs for the development of immunotherapy combinations
|
Seymour, L.
|
|
|
29 |
S3 |
p. iii2
|
article
|
| 68 |
Metabolic consequences of arginine deprivation in ASS1-deficient cancers
|
Van Tine, B.
|
|
|
29 |
S3 |
p. iii3
|
article
|
| 69 |
MicroRNA dysregulation as a prognostic biomarker in wild-type RAS/RAF/PTEN/PI3 metastatic colon cancer treated with anti-EGFR therapeutics
|
Aksoy, S.
|
|
|
29 |
S3 |
p. iii30
|
article
|
| 70 |
MicroRNA-21 functions as a prognosis predictor in head of pancreas tumor
|
Aksoy, F.
|
|
|
29 |
S3 |
p. iii14
|
article
|
| 71 |
miRNA 200c sensitize pancreatic cancer stem cells to carbon ion beam irradiation
|
Sai, S.
|
|
|
29 |
S3 |
p. iii13
|
article
|
| 72 |
mTORC1 and its downstream effectors predict poor outcome in primary epithelial ovarian cancer
|
Alabdullah, M.L.
|
|
|
29 |
S3 |
p. iii15
|
article
|
| 73 |
Multiphysics modelling of alpha-immuno-conjugate delivery and background dose
|
Liu, T.
|
|
|
29 |
S3 |
p. iii24
|
article
|
| 74 |
New insights in the antitumor effects of β-caryophyllene in breast cancer cells: The role of cannabinoid and adrenergic systems
|
Di Sotto, A.
|
|
|
29 |
S3 |
p. iii20
|
article
|
| 75 |
Novel effect of acetyl-11-keto-boswellic acid (AKBA) on mitophagy-induced apoptosis using cellular proteomic profiling
|
Al Zadjali, F.
|
|
|
29 |
S3 |
p. iii20
|
article
|
| 76 |
NOX66 plus low dose carboplatin: A phase 1 safety and signalling study
|
Kelly, G.
|
|
|
29 |
S3 |
p. iii11
|
article
|
| 77 |
Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model
|
Sharifi, Z.
|
|
|
29 |
S3 |
p. iii12
|
article
|
| 78 |
Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex
|
Weber, D.
|
|
|
29 |
S3 |
p. iii14
|
article
|
| 79 |
Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
|
Pegram, M.
|
|
|
29 |
S3 |
p. iii8
|
article
|
| 80 |
Pim1 promotes ovarian cancer growth and the Warburg effect via c-Myc-glycolysis signaling axis
|
Wu, Y.
|
|
|
29 |
S3 |
p. iii18-iii19
|
article
|
| 81 |
Precision trial designer-web: A web-based app to assist in the design of genomics-driven trials
|
Mazzarella, L.
|
|
|
29 |
S3 |
p. iii26
|
article
|
| 82 |
Preclinical evaluation of BET-bromodomain inhibitor TEN-010 as monotherapy and combination therapy in MYC-driven neuroblastoma
|
Firle, K.A.
|
|
|
29 |
S3 |
p. iii12-iii13
|
article
|
| 83 |
Preclinical testing of NEDD8 and proteasome inhbitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer patient
|
Torchiaro, E.
|
|
|
29 |
S3 |
p. iii31
|
article
|
| 84 |
Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer
|
Kawachi, A.
|
|
|
29 |
S3 |
p. iii27-iii28
|
article
|
| 85 |
Promoter hypermethylation of Wnt pathway inhibitor SFRP1 gene and its expression levels in human astrocytomas
|
Kafka, A.
|
|
|
29 |
S3 |
p. iii16
|
article
|
| 86 |
Protein expression and clinical significance of the NEDDylation pathway in myelodysplastic syndrome
|
Majidi, F.
|
|
|
29 |
S3 |
p. iii11
|
article
|
| 87 |
RAB25 a potential therapeutic target in luminal B breast cancer molecular subtype
|
Addou-Klouche, L.
|
|
|
29 |
S3 |
p. iii14-iii15
|
article
|
| 88 |
Real-life tolerance and plasma exposure assessment of lenvatinib in thyroid metastatic cancer patients
|
Goldwirt, L.
|
|
|
29 |
S3 |
p. iii27
|
article
|
| 89 |
Regulation of hnRNPA1 by microRNAs controls the miR-18a–K-RAS axis in chemotherapy-resistant ovarian cancer
|
Rodriguez-Aguayo, C.
|
|
|
29 |
S3 |
p. iii15-iii16
|
article
|
| 90 |
Relationship between functions and intracellular localization of the immune checkpoint target indoleamine 2,3-dioxygenase 1
|
Iacono, A.
|
|
|
29 |
S3 |
p. iii19
|
article
|
| 91 |
Repurposing chemotherapy drugs: The induction of immunogenic cell death in tumor cells as a tool leading to new formulations of cancer vaccines
|
Infante-Crúz, A.
|
|
|
29 |
S3 |
p. iii18
|
article
|
| 92 |
Re-sensitising endocrine resistant ER+ breast cancer by targeting epigenetic modifying enzymes
|
Borchert, G.
|
|
|
29 |
S3 |
p. iii16
|
article
|
| 93 |
Role of DNA methylation in early detection of gastric cancer in patient with chronic atrophied gastritis
|
Djuraev, F.
|
|
|
29 |
S3 |
p. iii17
|
article
|
| 94 |
Role of p21-activated kinase (PAK) in K-RAS mutant human colorectal cancer models
|
Orsini, R.C.
|
|
|
29 |
S3 |
p. iii16
|
article
|
| 95 |
4SC-202 plus anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma
|
Bartz, R.
|
|
|
29 |
S3 |
p. iii1-iii2
|
article
|
| 96 |
Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT
|
Cecchi, F.
|
|
|
29 |
S3 |
p. iii27
|
article
|
| 97 |
Self-questionnaire to assess patient’s preferences for participation in phase I clinical trials
|
Verret, B.
|
|
|
29 |
S3 |
p. iii32
|
article
|
| 98 |
Senescence after growth arrest: A mechanism by which CDK4/6 inhibitors can mediate their activity suppressing tumor progression
|
Koff, A.
|
|
|
29 |
S3 |
p. iii4
|
article
|
| 99 |
Sequencing of cancer panels through “next generation sequencing” (NGS) in the clinical practice of a phase 1 trial unit
|
Wiermann, A.L.
|
|
|
29 |
S3 |
p. iii25
|
article
|
| 100 |
Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer
|
Hermanowicz, J.M.
|
|
|
29 |
S3 |
p. iii17
|
article
|
| 101 |
Studies on the carcinogenic mechanisms of Growth Receptor Bound Protein 7 in breast cancer cells and its clinical therapeutic applications
|
Chen, L.-C.
|
|
|
29 |
S3 |
p. iii28-iii29
|
article
|
| 102 |
Sunitinib 4:2 versus 2:1 regimen
|
Parkar, R.
|
|
|
29 |
S3 |
p. iii31
|
article
|
| 103 |
Synergistic effects of PARP inhibitors and ionizing radiation on growth and survival of rhabdomyosarcoma cells
|
Megiorni, F.
|
|
|
29 |
S3 |
p. iii12
|
article
|
| 104 |
Table of Contents
|
|
|
|
29 |
S3 |
p. iv
|
article
|
| 105 |
Targeted anticancer therapy and concomitant hypofractionated radiotherapy in breast cancer
|
Bonzano, E.
|
|
|
29 |
S3 |
p. iii32-iii33
|
article
|
| 106 |
Targeted delivery of albumin-binding caspase-3 cleavable docetaxel prodrug to radiation exposed local tumor
|
Cho, Y.
|
|
|
29 |
S3 |
p. iii23
|
article
|
| 107 |
Targeting histone H3K36me3-deficient cancers
|
Humphrey, T.
|
|
|
29 |
S3 |
p. iii1
|
article
|
| 108 |
Targeting of the LXR-cholesterol axis as a metabolic co-dependency for brain cancers
|
Villa, G.
|
|
|
29 |
S3 |
p. iii3
|
article
|
| 109 |
Targeting Wnt pathway reduces primary tumor and metastasis in breast cancer models
|
Goswami, S.
|
|
|
29 |
S3 |
p. iii13
|
article
|
| 110 |
TAT 2018 Drug Index
|
|
|
|
29 |
S3 |
p. iii35
|
article
|
| 111 |
TAT 2018 Translational Research Index
|
|
|
|
29 |
S3 |
p. iii36-iii37
|
article
|
| 112 |
The clinical significance of lncRNA DANCR in upper rectal adenocarcinoma
|
Aksoy, F.
|
|
|
29 |
S3 |
p. iii33
|
article
|
| 113 |
The effect of hTERT repression on the TERRA expression and telomere length in gastric cancer
|
Akhavan, H.
|
|
|
29 |
S3 |
p. iii15
|
article
|
| 114 |
The function of cyclin D-CDK4/6 kinases in cancer cell metabolism and anti-tumor immune surveillance
|
Sicinski, P.
|
|
|
29 |
S3 |
p. iii4
|
article
|
| 115 |
The global forecast of prostate cancer drug-treatable populations eligible for targeted anticancer therapies (2017-2027)
|
Parihar, N.
|
|
|
29 |
S3 |
p. iii30
|
article
|
| 116 |
The next generation of radioimmunotherapy: Targeted alpha therapy (TAT)
|
Molnar, I.
|
|
|
29 |
S3 |
p. iii6
|
article
|
| 117 |
The predictive role of estrogen receptor beta (ER-β) in androgen receptor (AR)-positive triple-negative breast cancer (TNBC)
|
Anestis, A.
|
|
|
29 |
S3 |
p. iii32
|
article
|
| 118 |
The relationship between DNA damage and immune checkpoint activation in cancer
|
Kennedy, R.
|
|
|
29 |
S3 |
p. iii3-iii4
|
article
|
| 119 |
The role of citrus peel extract in inhibiting progression and recurrence of prostate cancer
|
Shammugasamy, B.
|
|
|
29 |
S3 |
p. iii24
|
article
|
| 120 |
The role of topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer
|
Gamea, M.
|
|
|
29 |
S3 |
p. iii33
|
article
|
| 121 |
To assess the pain control and tolerance to drug induced emesis in oral and neck carcinoma patients undergoing chemoradiation treated for pain relief with tapentadol (TAPAL -ER 50) vs. tramadol plus paracetamol with and without anti-emetic support
|
Narayanasamy, R.
|
|
|
29 |
S3 |
p. iii29
|
article
|
| 122 |
Towards the identification of the mechanism of action of antitumor 1-methyl-D-tryptophan
|
Pallotta, M.T.
|
|
|
29 |
S3 |
p. iii19
|
article
|
| 123 |
TREX1 as a gate-keeper of cGAS/STING-mediated activation of interferon type I in cancer cells treated with DNA-damaging agents
|
Demaria, S.
|
|
|
29 |
S3 |
p. iii1
|
article
|
| 124 |
Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
|
Roberts, P.J.
|
|
|
29 |
S3 |
p. iii4
|
article
|
| 125 |
Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials
|
Banerji, U.
|
|
|
29 |
S3 |
p. iii7
|
article
|
| 126 |
Up-regulation of miR-1266-5p suppressed hTERT expression and telomerase activity in cancer cell lines
|
Hosseini-Asl, S.S.
|
|
|
29 |
S3 |
p. iii15
|
article
|
| 127 |
Vascular targeted photodynamic therapy for pancreatic ductal adenocarcinoma: A pre-clinical success
|
Goldschmidt, R.
|
|
|
29 |
S3 |
p. iii21
|
article
|
| 128 |
Vulnerabilities of IDH mutant gliomas
|
Cahill, D.
|
|
|
29 |
S3 |
p. iii2-iii3
|
article
|
| 129 |
Why is PI3K so hard?
|
Scaltriti, M.
|
|
|
29 |
S3 |
p. iii4
|
article
|
Journal description